Heather E Eve

Learn More
The National Cancer Research Network (NCRN) is currently coordinating a Phase III randomised study (LY05) comparing fludarabine and cyclophosphamide (FC) with or without rituximab (R) for previously(More)
Mantle cell lymphoma (MCL) remains an incurable hematological malignancy with a median overall survival (OS) of 3–5 years. The clinical course can be extremely variable with some individuals(More)
  • 1